Study guide

2.3 Tolerance, Withdrawal, Craving, and Cross-Tolerance

IC&RC Alcohol and Drug Counselor CADC

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Orientation, IC&RC ADC Exam, and Credential Path

1.1 ADC Credential, IC&RC, and CADC Naming 1.2 Administering Board Application Workflow 1.3 Minimum Standards and Eligibility Boundaries 1.4 ADC Blueprint and Study Priorities 1.5 Exam Format, Items, and Time Management 1.6 Scores, Results, Retakes, and Remediation 1.7 Exam-Day Admission, In-Person Testing, and Remote Testing

2 Chapter 2: Addiction Science, Substance-Use Patterns, and Risk Factors

2.1 Disease Model and Biopsychosocial Frame 2.2 Reward Pathways, Learning, and Reinforcement 2.3 Tolerance, Withdrawal, Craving, and Cross-Tolerance 2.4 Substance-Use Progression and Severity Patterns 2.5 Risk and Protective Factors Across the Lifespan 2.6 Prevention, Case Conceptualization, and Domain Integration

3 Substance Classes, Intoxication, Overdose, and Withdrawal

3.1 Alcohol Intoxication, Overdose, and Withdrawal 3.2 Sedatives, Hypnotics, Anxiolytics, and Cross-Tolerance 3.3 Opioids: Intoxication, Overdose, and Withdrawal 3.4 Stimulants: Intoxication, Crash, and Crisis Risk 3.5 Cannabis, Hallucinogens, and Inhalants 3.6 Polysubstance Use and Overdose Triage

4 Co-Occurring Mental Health, Medical, and Trauma Concerns

4.1 Co-Occurring Symptoms and Integrated Screening 4.2 Suicide, Self-Harm, and Crisis Triage 4.3 Medical Red Flags and Substance-Related Health Concerns 4.4 Trauma-Informed Care and ACEs 4.5 Special Populations, Developmental, and Cultural Factors 4.6 Scope, Referral, Collaboration, and Documentation

5 Screening, Interviewing, and Assessment Instruments

5.1 Motivational Assessment Interview Stance 5.2 Screening Purpose and Instrument Selection 5.3 Substance-Use History and Pattern Exploration 5.4 Collateral Information and Testing Interpretation 5.5 Risk, Withdrawal, and Immediate Needs Screening 5.6 Engagement, Culture, and Documentation

6 Diagnosis, Biopsychosocial Assessment, and Level of Care

6.1 Diagnostic Concepts and Scope 6.2 Biopsychosocial Assessment Framework 6.3 Immediate and Ongoing Needs 6.4 Level-of-Care Placement Reasoning 6.5 Case Formulation and Assessment Summary 6.6 Documentation, Referral, and Reassessment

7 Counseling Relationship, Communication, and Motivational Interviewing

7.1 Rapport and the Working Alliance 7.2 Core Communication Skills 7.3 OARS and Reflective Listening 7.4 Ambivalence, Resistance, and Discord 7.5 Change Talk and Stages of Change 7.6 Feedback and Counselor Style

8 Treatment Planning, Case Management, and Referral

8.1 Treatment Plan Anatomy 8.2 Individualized Goals and Objectives 8.3 Relapse Prevention and Continuing Care 8.4 Case Management and Resource Linkage 8.5 Referral and Multidisciplinary Collaboration 8.6 Discharge, Termination, and Continuity of Care

9 Group Counseling, Family Work, and Recovery Pathways

9.1 Group Purpose, Screening, and Norms 9.2 Group Stages, Cohesion, and Facilitation Skills 9.3 Psychoeducation, Skills Groups, and Process Groups 9.4 Family and Support-System Collaboration 9.5 Mutual Help, Peer Support, and Recovery Pathways 9.6 Medication, Culture, and Continuing Care

10 Professional Ethics, Boundaries, and Scope of Practice

10.1 Ethical Frameworks and Decision Making 10.2 Boundaries, Dual Relationships, and Power 10.3 Self-Disclosure, Conflicts of Interest, and Gifts 10.4 Scope of Practice, Competence, and Referral 10.5 Supervision, Consultation, and Team Accountability 10.6 Self-Awareness, Impairment, and Burnout

11 Confidentiality, Documentation, Informed Consent, and Client Rights

11.1 Confidentiality Foundations for ADC Practice 11.2 Releases and Minimum Necessary Disclosure 11.3 Documentation and Record Quality 11.4 Informed Consent and Client Rights 11.5 Mandated Reporting and Safety Exceptions 11.6 Grievances, Records, Storage, and Professional Communication

12 Integrated CADC Case Scenarios and Final Review

12.1 Reading Integrated Case Vignettes 12.2 Blueprint-Weighted Final Review 12.3 Integrated Scenario: First Contact Through Assessment 12.4 Integrated Scenario: Treatment, Referral, and Discharge 12.5 Weak-Domain Remediation and 8-12 Week Study Plan 12.6 Exam Day, Results, and Retake Workflow

2.3 Tolerance, Withdrawal, Craving, and Cross-Tolerance

Key Takeaways Explain This Topic AI

Tolerance means needing more of a substance for the same effect, or getting less effect from the same dose, due to neuroadaptation.

Withdrawal is the predictable, substance-specific syndrome that emerges when a dependent person reduces or stops use.

CNS-depressant withdrawal (alcohol, benzodiazepines) can be life-threatening (seizures, delirium tremens); opioid withdrawal is severe but rarely fatal.

Physical dependence is not the same as addiction; a person can be dependent on a prescribed medication without a substance use disorder.

Cross-tolerance occurs between drugs in the same class (e.g., alcohol and benzodiazepines), which is why medical detox often uses a substituting agent.

Last updated: June 2026

Tolerance and neuroadaptation

Tolerance is a state in which a person needs more of a substance to achieve the original effect, or experiences a diminished effect from the same dose. It reflects the brain and body adapting to repeated exposure (neuroadaptation). The exam distinguishes several forms:

Metabolic (pharmacokinetic) tolerance: the liver clears the drug faster (e.g., induced enzymes for alcohol).

Cellular/pharmacodynamic tolerance: receptors and circuits become less responsive.

Behavioral/learned tolerance: the person learns to compensate for impairment in familiar settings.

Acute tolerance (the Mellanby effect): within a single episode, impairment is greater on the rising blood-alcohol limb than on the falling limb.

Reverse tolerance (sensitization): increased response over time, seen with some stimulants and in late-stage liver disease where less alcohol produces more impairment.

A dangerous clinical point: tolerance to a drug's desired effects often outpaces tolerance to its lethal effects, narrowing the margin between an intoxicating and a fatal dose — a major driver of overdose, especially with opioids and depressants.

Dependence vs. addiction, and withdrawal by class

Physical dependence means the body has adapted such that stopping produces withdrawal . It is not the same as addiction. A patient taking opioids for chronic pain, or an antidepressant, can be physically dependent without meeting criteria for a substance use disorder (which requires the compulsive, harmful pattern from Domain II). Conflating the two is a classic exam trap and a stigma risk.

Withdrawal is substance-specific and roughly mirrors the drug's effects. The single most safety-critical fact for the ADC exam:

Drug class Withdrawal danger Key features

CNS depressants (alcohol, benzodiazepines, barbiturates) Potentially fatal Tremor, anxiety, autonomic arousal, seizures , delirium tremens ; requires medically supervised detox

Opioids Very uncomfortable, rarely fatal in healthy adults Nausea, diarrhea, muscle aches, yawning, dilated pupils, 'flu-like' misery; overdose (not withdrawal) is the lethal risk

Stimulants (cocaine, methamphetamine) Not directly fatal 'Crash': fatigue, hypersomnia, depression, suicidal ideation , intense craving

CIWA-Ar is the standard tool for alcohol withdrawal severity; COWS is the standard tool for opioid withdrawal. The counselor screens and refers — these tools guide medical management.

Craving, cross-tolerance, and counselor scope

Craving is an intense subjective urge to use, now formally one of the DSM-5 substance use disorder criteria. It can be triggered by conditioned cues, stress, negative emotions, withdrawal, or re-exposure to even a small amount of the substance (a 'priming' dose). Because craving is cue- and stress-driven, counseling targets trigger identification, urge-surfing, coping skills, and stress reduction.

Cross-tolerance occurs when tolerance to one drug produces tolerance to another drug in the same pharmacological class . Alcohol, benzodiazepines, and barbiturates are cross-tolerant CNS depressants — which is why a physician may use a substituting agent (e.g., a longer-acting benzodiazepine) to safely taper alcohol withdrawal. Cross-dependence is the related idea that one drug can prevent or relieve another's withdrawal (the basis of methadone or buprenorphine for opioids).

Worked scenario and scope limits

A client reports drinking a pint of vodka daily plus daily alprazolam (Xanax) and now feels shaky with a racing heart after trying to stop cold. The safest next step is immediate referral for medical evaluation/detox , because combined CNS-depressant withdrawal carries seizure and delirium-tremens risk.

' Exam trap: answers that keep a high-risk depressant-withdrawal client in outpatient counseling without medical clearance, or that treat opioid withdrawal as the deadliest scenario — depressant withdrawal and opioid overdose are the lethal pairings to remember.

Protracted withdrawal and the recovery timeline

Acute withdrawal is only the first phase. Many clients experience post-acute withdrawal syndrome (PAWS) — weeks to months of fluctuating sleep disturbance, mood instability, irritability, anxiety, low energy, and intermittent craving as the brain slowly re-regulates. PAWS is high-yield because clients (and sometimes counselors) misread it as personal failure or as evidence that 'recovery isn't working,' when it is an expected neuroadaptive recovery process.

Normalizing PAWS, supporting sleep and routine, and maintaining recovery supports through this window reduces relapse risk. The exam favors answers that frame lingering symptoms as a predictable phase to be managed rather than a reason to abandon the plan.

Why these concepts drive assessment and referral

Tolerance, withdrawal, craving, and cross-tolerance are tested precisely because they sit at the boundary of the counselor's scope. They tell the counselor when to refer . Reported high tolerance and a history of withdrawal signal physiological dependence and possible need for medically supervised detox and medication for addiction treatment (MAT) — methadone or buprenorphine for opioids, naltrexone for opioids or alcohol, acamprosate and disulfiram for alcohol. The counselor screens for withdrawal severity with CIWA-Ar (alcohol) or COWS (opioids) , documents the pattern, and connects the client to medical care.

The scope line is firm: the ADC counselor assesses, screens, educates, supports, and refers , but does not diagnose medical conditions, prescribe, recommend dosing, or supervise detoxification. Recognizing the clinical meaning of these phenomena — and the safest next step — is what the exam measures, not the ability to manage them medically. Holding that line protects the client and keeps the counselor within ethical and legal scope of practice.